IRBESARTAN IN THE CLINICAL PRACTICE

Show other versions (1)

Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the...

Full description

Bibliographic Details
Published in:	Рациональная фармакотерапия в кардиологии
Main Authors:	V. I. Podzolkov, A. I. Tarzimanova
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Subjects:	irbesartan angiotensin receptor blockers arterial hypertension nephroprotection
Online Access:	https://www.rpcardio.online/jour/article/view/306

Similar Items

APPROACHES TO SELECTION OF ANTIHYPERTENSION DRUG WITHIN APPLIED LOWER TARGET BLOOD PRESSURE LEVELS
by: S. R. Gilyarevsky, et al.
Published: (2017-12-01)

Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
by: V. V. Fomin
Published: (2013-12-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Nephroprotective strategy in the treatment of hypertension as a modern general medical problem
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

CARDIOVASCULAR PATIENT WITH STAGE 1-3 CHRONIC KIDNEY DISEASE: CONTEMPORARY CARDIONEPHROPROTECTION IN REAL CLINICAL PRACTICE
by: E. I. Tarlovskaya
Published: (2016-09-01)

Effect of Irbesartan on Chemerin in the Renal Tissues of Diabetic Rats
by: Qiu-Xia Yu, et al.
Published: (2015-09-01)

The effect of the <i>M235T</i> polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-12-01)

Clinical efficacy of benazepril and irbesartan for children with chronic glomerulonephritis
by: LIU Xiao-yan
Published: (2016-01-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Determination of Irbesartan in Pharmaceutical Preparations by HPLC
by: Bilal Yılmaz
Published: (2025-06-01)

Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
by: Tingting Zhou, et al.
Published: (2017-10-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model
by: Sabeen Shakir, et al.
Published: (2024-05-01)

Rhabdomyolysis Induced by Irbesartan‐Hydrochlorothiazide in an Elderly Patient
by: Wei Yang, et al.
Published: (2025-10-01)

Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia
by: Ihm SH, et al.
Published: (2019-02-01)

Irbesartan attenuates renal injury with diabetic nephropathy rats
by: ZHANG Ya, HUANG Wen-hui, HOU Zhi-min, LIU Ju-xiang, LIU Jing
Published: (2020-04-01)

Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation
by: Petrov Andrey D., et al.
Published: (2018-01-01)

Irbesartan; An Antihypertensive Drug Reduces LDL-Cholesterol in Diet Induced Hyperlipidemic Rabbits
by: Sabeen Shakir , Akbar Waheed , Noureen Hafeez
Published: (2016-09-01)

Efficiency assessment for antihypertensive, hemodynamic, renal effects of adenosine-converting enzyme (ACE) inhibitors and irbesartan and impact on endothelial disfunction in patients with stage II hypertension
by: M. V. Pereviazkina
Published: (2014-08-01)

Effect of Irbesartan on TRPC6 expression in high glucose-induced mouse podocytes
by: HU Chun-li, et al.
Published: (2016-01-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

New targets and old therapies for arterial hypertension
by: S. R. Gilyarevsky, et al.
Published: (2019-04-01)

HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets
by: Alanazi Amer M., et al.
Published: (2014-06-01)

The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations
by: Kamryn E. Jones, et al.
Published: (2024-06-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy
by: Noriaki Nagai, et al.
Published: (2022-02-01)

MONO- OR COMBINED ANTIHYPERTENSIVE THERAPY IN WOMEN WITH ARTERIAL HYPERTENSION AND MODERATE RISK OF CARDIOVASCULAR DISEASES: WHAT’S BETTER?
by: R. I. Stryuk, et al.
Published: (2018-01-01)

Metabolic syndrome and angiotensin II receptor antagonists
by: K. M. Mamyrbayeva, et al.
Published: (2007-04-01)

Nanocrystalline Suspensions of Irbesartan Enhance Oral Bioavailability by Improving Drug Solubility and Leading Endocytosis Uptake into the Intestine
by: Saori Deguchi, et al.
Published: (2021-09-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Pharmacokinetic interaction between irbesartan and Orthosiphon stamineus extract in rat plasma
by: Nur Meilis, et al.
Published: (2016-02-01)

Left ventricular hypertrophy: renin4angiotensin system role
by: F. T. Ageev, et al.
Published: (2008-04-01)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
by: Radko Komers, et al.
Published: (2017-07-01)

Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW)
by: Pınar Kızılırmak, et al.
Published: (2014-06-01)

Irbesartan ameliorates inflammation via transendothelial leukocyte migration due to VCAM-1/NOX-1 signaling in cisplatin-induced cardiotoxicity
by: Dilek Ulusoy Karatopuk, et al.
Published: (2023-11-01)

Seven New Irbesartan Salts: Significantly Improved Dissolution, Excellent Hygrothermal Stability, and Characteristic Supramolecular Synthons
by: Junxiao Wang, et al.
Published: (2025-04-01)

Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization
by: Narendar Dudhipala, et al.
Published: (2021-12-01)